Stoke Therapeutics (NASDAQ:STOK) Releases Earnings Results, Beats Estimates By $0.05 EPS

Stoke Therapeutics (NASDAQ:STOK) released its earnings results on Tuesday. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05, Zacks reports. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $3.46 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%.

Stoke Therapeutics Stock Performance

Shares of STOK traded down $0.01 during trading hours on Thursday, hitting $13.24. The company had a trading volume of 194,439 shares, compared to its average volume of 760,410. Stoke Therapeutics has a 52-week low of $3.77 and a 52-week high of $17.58. The firm has a fifty day moving average price of $13.24 and a 200-day moving average price of $13.70. The stock has a market capitalization of $697.06 million, a price-to-earnings ratio of -6.08 and a beta of 0.95.

Insider Buying and Selling at Stoke Therapeutics

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.30% of the stock is owned by company insiders.

Analyst Ratings Changes

STOK has been the subject of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $17.00 price objective on shares of Stoke Therapeutics in a report on Thursday, July 11th. Leerink Partners started coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and an average price target of $20.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.